$-0.07
(Market cap
$70 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-53 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
36,150,800
10 Years Aggregate
CFO
$-150.16 Mln
EBITDA
$-227.06 Mln
Net Profit
$-228.49 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cortexyme (CRTX)
| -89.5 | -22.7 | -41.2 | -98.6 | -62.2 | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
Company
|
2021
|
2020
|
|---|---|---|
|
Cortexyme (CRTX)
| -54.6 | -50.5 |
|
BSE Sensex
| 22.0 | 15.8 |
|
BSE Sensex
| 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cortexyme (CRTX)
|
1.3 | 70.5 | 0.0 | -136.1 | -- | -129.8 | -- | 0.7 |
| 84.9 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 72.3 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.2 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.3 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 350.5 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 534.5 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 603.9 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 348.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 142.6 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Cortexyme (CRTX)
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule... gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Read more
-
Exec. VP of R&D
Dr. Leslie J. Holsinger Ph.D.
-
Exec. VP of R&D
Dr. Leslie J. Holsinger Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cortexyme (CRTX)
What is the current share price of Cortexyme Inc (CRTX) Today?
The share price of Cortexyme Inc (CRTX) is $1.33 (NASDAQ) as of 30-Sep-2022 09:30 EDT. Cortexyme Inc (CRTX) has given a return of -62.21% in the last 3 years.
What is the current PB & PE ratio of Cortexyme Inc (CRTX)?
Since, TTM earnings of Cortexyme Inc (CRTX) is negative, P/E ratio is not available.
The P/B ratio of Cortexyme Inc (CRTX) is 0.66 times as on 30-Sep-2022, a 88 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
2017 |
-- |
-- |
What is the 52 Week High and Low of Cortexyme Inc (CRTX)?
The 52-week high and low of Cortexyme Inc (CRTX) are Rs -- and Rs -- as of 30-Aug-2026.
What is the market cap of Cortexyme Inc (CRTX)?
Cortexyme Inc (CRTX) has a market capitalisation of $ 70 Mln as on 30-Sep-2022. As per SEBI classification, it is a company.
Should I invest in Cortexyme Inc (CRTX)?
Before investing in Cortexyme Inc (CRTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.